{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-000527","form_type":"8-K/A","ticker":"AUPH","cik":"0001600620","company_name":"Aurinia Pharmaceuticals Inc.","filed_at":"2022-01-07T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.303052+00:00","generated_at":"2026-06-27T19:52:30.314757+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Aurinia reports positive 3-year AURORA 2 data for LUPKYNIS; no new safety signals","bullets":["eGFR stable over 36 months; +2.7 mL/min vs control from baseline.","Serious AE rates: 19% voclosporin vs 24% control; 0 deaths in voclosporin arm vs 4 in placebo.","Mean UPCR lower in voclosporin group at all time points over 3 years.","Withdrawal rate: 12.9% voclosporin vs 15.0% control; drug well tolerated.","AURORA 2 enrolled 216 LN patients; 90 voclosporin and 78 control completed 36 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-000527","json":"https://secwatch.observer/filing/0001628280-22-000527.json","markdown":"https://secwatch.observer/filing/0001628280-22-000527.md","text":"https://secwatch.observer/filing/0001628280-22-000527.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1600620/000162828022000527/0001628280-22-000527-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1600620/000162828022000527/auph-20211209.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T19:52:30.314757+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}